| Literature DB >> 32592365 |
Manal Nasreddin Eldaly1, Fateheya Mohamed Metwally2, Wafaa Ghoneim Shousha1, Abeer Salah El-Saiid3, Shimaa Shawki Ramadan1.
Abstract
INTRODUCTION: Colorectal cancer (CRC) is the most common type of gastrointestinal tract cancers. This investigation aim was to assess the expression of miR-576-3p and miR-613 in CRC patients in addition to NDRG2 and YKL40 serum levels determination to decide their diagnostic and prognostic significance.Entities:
Keywords: Colon cancer; Diagnostic; micro RNA; molecular biomarkers
Year: 2020 PMID: 32592365 PMCID: PMC7568881 DOI: 10.31557/APJCP.2020.21.6.1689
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Cycling Conditions for SYBR Green Real-Time PCR According to Quantitect SYBR Green PCR kit
| Gene | Reverse | Primary | Amplification (40 cycles) | Dissociation curve (1 cycle) | ||||
|---|---|---|---|---|---|---|---|---|
| Secondary denaturation | Annealing (Optics on) | Extension | Secondary denaturation | Annealing | Final | |||
|
| 50˚C | 94˚C | 94˚C | 58˚C | 72˚C | 94˚C | 58˚C | 94˚C |
| 30 min. | 5 min. | 15 sec. | 30 sec. | 30 sec. | 1 min. | 1 min. | 1 min. | |
|
| 50˚C | 94˚C | 94˚C | 60˚C | 72˚C | 94˚C | 60˚C | 94˚C |
| 30 min. | 5 min. | 15 sec. | 30 sec. | 30 sec. | 1 min. | 1 min. | 1 min. | |
|
| 50˚C | 94˚C | 94˚C | 60˚C | 72˚C | 94˚C | 60˚C | 94˚C |
| 30 min. | 5 min. | 15 sec. | 30 sec. | 30 sec. | 1 min. | 1 min. | 1 min. | |
RNA Specific Primers for miR-576-3p, miR-613 and Housekeeping Gene (Human GAPDH)
| Gene | Primer sequence (5'-3') | Reference |
|---|---|---|
|
| CTCTGATTTGGTCGTATTGGG | (Li et al., 2014) |
| TGGAAGATGGTGATGGGATT | ||
|
| AAGATGTGGAAAAATTGGAATC | (Liang et al., 2015) |
| ATTCTAATTTCTCCACGTCTTT | ||
|
| CCGCTCGAGTCTACTAGGTGTGGGCTTTA | (Ou et al., 2011) |
| CCCAAGCTTCTGTGGCCTTCCTTACTCTT |
The Mean Levels of Parameters of the Patients Compared with Those of Control
| Parameters | Patients | Control |
|
|---|---|---|---|
| HB (gm/dl) | 10.49 ± 0.20 | 13.32 ± 0.30 | <0.001* |
| Platelets (x103/mm3) | 414.63 ± 20.52 | 291.50 ± 18.12 | 0.1 |
| WBCs(x103/mm3) | 8.99 ± 0.38 | 6.55 ± 0.41 | 0.007* |
| CEA (ng/ml) | 36.55 ± 9.02 | 1.85 ± 0.27 | 0.09 |
| CA 19-9 (U/ml) | 271.05 ± 166.06 | 5.25 ± 1.16 | 0.48 |
| miR-576 delta Ct | 3.97± 0.21 | 2.38 ± 0.24 | 0.002* |
| miR-613 delta Ct | 4.15 ± 0.21 | 2.69 ± 0.30 | 0.003* |
| NDRG2 (pg/ml) | 3.03 ± 0.18 | 3.17 ± 0.54 | 0.75 |
| YKL40 (pg/ml) | 3813.40 ± 251.38 | 731.50 ± 119.35 | <0.001* |
Data were expressed as mean ± standard error of mean; *, is significant.
Data Analysis of miR-576-3p in the Studied Groups
| Group (%) | GAPDH Ct | miR-576-3p Ct | ∆Ct | ∆∆Ct | Fc |
|---|---|---|---|---|---|
| Control | 19.45 | 21.83 | 2.38 | 0 | 1 |
| Total patients | 20.86 | 24.83 | 3.97 | 1.59 | 0.33 |
| Grade: | |||||
| II (86.96%) | 20.93 | 24.91 | 3.98 | 1.6 | 0.33 |
| III (13.04%) | 20.23 | 24.09 | 3.86 | 1.48 | 0.36 |
| Stage: | |||||
| I (13.04%) | 19.25 | 24.81 | 5.56 | 3.18 | 0.11 |
| IIA (30.43%) | 21.64 | 27.18 | 5.54 | 3.16 | 0.11 |
| IIIA(13.04%) | 19.85 | 24.38 | 4.53 | 2.15 | 0.23 |
| IVA (13.04%) | 19.94 | 23.83 | 3.89 | 1.51 | 0.35 |
| IIB (4.35%) | 20.93 | 24.86 | 3.93 | 1.55 | 0.34 |
| IIIB (21.75%) | 21.27 | 25.83 | 4.56 | 2.18 | 0.22 |
| IIIC (4.35%) | 21.76 | 25.24 | 3.48 | 1.10 | 0.47 |
| Tumor Site: | |||||
| Colon (65.22%) | 20.76 | 24.69 | 3.93 | 1.55 | 0.34 |
| Rectum (30.43%) | 21.06 | 25.2 | 4.14 | 1.76 | 0.3 |
| Colon & Rectum | 21.76 | 25.24 | 3.48 | 1.10 | 0.47 |
| Lymph Node: | |||||
| Positive (56.52%) | 20.78 | 25.22 | 4.44 | 2.06 | 0.24 |
| Negative (43.48%) | 20.84 | 24.8 | 3.96 | 1.58 | 0.33 |
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; Ct, Cycle threshold; Fc, Fold change.
Data Analysis of miR-613 in the Studied Groups
| Group (%) | GAPDH Ct | miR-613 Ct | ∆Ct | ∆∆Ct | Fc |
|---|---|---|---|---|---|
| Control | 19.45 | 22.14 | 2.69 | 0 | 1 |
| Total patients | 20.86 | 25.01 | 4.15 | 1.46 | 0.36 |
| Grade: | |||||
| II (86.96) | 20.93 | 25.11 | 4.18 | 1.49 | 0.36 |
| III(13.04%) | 20.23 | 24.13 | 3.9 | 1.21 | 0.43 |
| Stage: | |||||
| I (13.04%) | 19.25 | 24.32 | 5.07 | 2.38 | 0.19 |
| IIA (30.43%) | 21.64 | 25.44 | 3.8 | 1.11 | 0.46 |
| IIIA (13.04%) | 19.85 | 24.11 | 4.26 | 1.57 | 0.34 |
| IVA (13.04%) | 19.94 | 24.47 | 4.53 | 1.84 | 0.28 |
| IIB (4.35%) | 21.94 | 25.16 | 3.22 | 0.53 | 0.69 |
| IIIB (21.75%) | 21.27 | 26.31 | 5.04 | 2.35 | 0.2 |
| IIIC (4.35%) | 21.76 | 24.72 | 2.96 | 0.27 | 0.83 |
| Tumor Site: | |||||
| Colon (65.22%) | 20.76 | 24.87 | 4.11 | 1.42 | 0.37 |
| Rectum (30.43%) | 21.06 | 25.49 | 4.43 | 1.74 | 0.3 |
| Colon & Rectum | 21.76 | 24.72 | 2.96 | 0.27 | 0.83 |
| Lymph Node: | |||||
| Positive (56.52%) | 20.78 | 25.26 | 4.48 | 1.79 | 0.29 |
| Negative (43.48%) | 20.84 | 24.96 | 4.12 | 1.43 | 0.37 |
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; Ct, Cycle threshold; Fc, Fold change
Serum Mean Levels of Parameters According to the Clinicopathological Data of the Patients
| Grade | miR-576-3p | miR-613 | NDRG2 | YKL40 |
|---|---|---|---|---|
| II | 0.54 ± 0.06 | 0.54 ± 0.05 | 2.88 ± 0.18 | 3742.56 ± 264.18 |
| III | 0.50 ± 0.19 | 0.50 ± 0.14 | 4.34 ± 0.76 | 4923,33 ± 26,67 |
|
| 0.82 | 0.83 | 0.02* | 0.27 |
| Stage | ||||
| I | 0.14 ± 0.05 | 0.41 ± 0.19 | 2.97 ± 0.30 | 5125.00 ± 72.17 |
| IIA | 0.67 ± 0.12 | 0.64 ± 0.10 | 3.26 ± 0.21 | 3220.00 ± 516.68 |
| IIIA | 0.23 ± 0.02 | 0.35 ± 0.05 | 4.33 ± 0.76 | 3502.00 ± 870.51 |
| IVA | 0.56 ± 0.19 | 0.50 ± 0.17 | 2.28 ± 0.23 | 5116,67 ± 158.33 |
| IIB | 0.69 ± 0.03 | 0.69 ± 0.03 | 2.36 ± 0.06 | 3525.00 ± 75.00 |
| IIIB | 0.43 ± 0.14 | 0.35 ± 0.11 | 3.10 ± 0.48 | 3312.00 ± 659.80 |
| IIIC | 0.47 ± 0.02 | 0.83 ± 0.03 | 1.65 ± 0.05 | 2370.05 ± 0.05 |
|
| 0.09 | 0.3 | 0.04* | 0.28 |
| Tumor Site | ||||
| Colon | 0.56 ± 0.06 | 0.56 ± 0.06 | 2.89 ± 0.19 | 3727.43 ± 300.50 |
| Rectum | 0.49 ± 0.12 | 0.43 ± 0.08 | 3.63 ± 0.49 | 4266.92 ± 508.02 |
| Colon & rectum | 0.47 ± 0.02 | 0.83 ± 0.03 | 1.65 ± 0.05 | 2370.05 ± 0.05 |
| P-Value | 0.85 | 0.24 | 0.33 | 0.09 |
| Lymph Node | ||||
| Positive | 0.39 ± 0.07 | 0.43 ± 0.06 | 3.12 ± 0.30 | 3732.73 ± 399.47 |
| Negative | 0.57 ± 0.10 | 0.59 ± 0.09 | 3.05 ± 0.18 | 3453.57 ± 376.05 |
|
| 0.12 | 0.14 | 0.86 | 0.64 |
Data were expressed as mean ± standard error of mean; *, is significant.
Correlation between Parameters in the CRC Patients
| CEA | CA19-9 | miR-576-p | miR-613 | NDRG2 | |
|---|---|---|---|---|---|
| CA19-9 | |||||
|
| -0.04 | ||||
|
| 0.75 | ||||
| miR-576-3p | |||||
|
| -0.3 | -0.21 | |||
|
| 0.82 | 0.1 | |||
| miR-613 | |||||
|
| -0.07 | -0.27 | 0.75 | ||
|
| 0.56 | 0.04* | <0.001** | ||
| NDRG2 | |||||
|
| -0.37 | -0.01 | -0.12 | -0.16 | |
|
| 0.004** | 0.96 | 0.35 | 0.23 | |
| YKL40 | |||||
|
| -0.21 | 0.17 | 0.15 | 0.13 | 0.1 |
|
| 0.13 | 0.23 | 0.3 | 0.34 | 0.44 |
*, is significant; **, is highly significant; r, Pearson’s correlation coefficient; p, probability value.
The Sensitivity, Specificity, Cut off Value, and AUC (area under curve) for NDRG2 and YKL40 in Colorectal Cancer Patients
| Parameters | Sensitivity (%) | Specificity (%) | Cut off Value | Area Under Curve |
|
|---|---|---|---|---|---|
| NDRG2 | 60 | 66.7 | <2.5 | 0.54 | 0.64 |
| YKL40 | 96 | 91.7 | <1200 | 0.97 | 0.0001 |
Figure 1ROC Curve of YKL40 in CRC Patients Compared to Control; - Specificity: 91.7%, Sensitivity: 96%, Cut off: > 1200, AUC: 0.97
Figure 2ROC Curve of NDRG2 in CRC Patients Compared to Control; -Specificity: 66.7%, Sensitivity: 60%, Cut off: > 2.5, AUC: 0.54